Mucosal delivery of antigens using adsorption to bacterial spores

Vaccine
Jen-Min HuangSimon M Cutting

Abstract

The development of new-generation vaccines has followed a number of strategic avenues including the use of live recombinant bacteria. Of these, the use of genetically engineered bacterial spores has been shown to offer promise as both a mucosal as well as a heat-stable vaccine delivery system. Spores of the genus Bacillus are currently in widespread use as probiotics enabling a case to be made for their safety. In this work we have discovered that the negatively charged and hydrophobic surface layer of spores provides a suitable platform for adsorption of protein antigens. Binding can be promoted under conditions of low pH and requires a potent combination of electrostatic and hydrophobic interactions between spore and immunogen. Using appropriately adsorbed spores we have shown that mice immunised mucosally can be protected against challenge with tetanus toxin, Clostridium perfringens alpha toxin and could survive challenge with anthrax toxin. In some cases protection is actually greater than using a recombinant vaccine. Remarkably, killed or inactivated spores appear equally effective as live spores. The spore appears to present a bound antigen in its native conformation promoting a cellular (T(h)1-biased) response coupled wi...Continue Reading

References

Oct 10, 1986·Nucleic Acids Research·N F Fairweather, V A Lyness
Oct 1, 1995·European Journal of Immunology·K J MaloyA M Mowat
Jun 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·M Kovacsovics-BankowskiK L Rock
Nov 27, 1998·Nature Biotechnology·S Raychaudhuri, K L Rock
Mar 23, 2000·FEMS Immunology and Medical Microbiology·D BumannT F Meyer
Apr 20, 2001·Journal of Microbiological Methods·F AhimouP G Rouxhet
Oct 10, 2001·Journal of Bacteriology·R IsticatoE Ricca
Aug 20, 2002·Vaccine·Robert L Hunter
Apr 22, 2003·Infection and Immunity·Le H DucSimon M Cutting
Mar 1, 1995·Trends in Cell Biology·C V Harding
Mar 30, 2004·Current HIV Research·Manmohan Singh, Indresh Srivastava
Oct 12, 2004·Vaccine·Annalisa CiabattiniGianni Pozzi
Dec 30, 2004·The Journal of Experimental Medicine·Ki-Jong RheeKatherine L Knight
Jan 14, 2005·Journal of Environmental Quality·L PangP van den Brink
Feb 5, 2005·Applied and Environmental Microbiology·Teresa M BarbosaAdriano O Henriques
Aug 17, 2005·FEMS Microbiology Reviews·Huynh A HongSimon M Cutting
Nov 25, 2005·Current Drug Delivery·P M MoyleI Toth
Mar 21, 2006·Journal of Bacteriology·Nguyen K M TamSimon M Cutting
Jun 27, 2006·Microbial Cell Factories·Ann Detmer, Jacob Glenting
Nov 24, 2007·Annual Review of Microbiology·Adriano O Henriques, Charles P Moran
Dec 11, 2008·Research in Microbiology·Huynh A HongSimon M Cutting

❮ Previous
Next ❯

Citations

Mar 8, 2011·Analytical and Bioanalytical Chemistry·Leslie D KnechtSylvia Daunert
Mar 14, 2013·Journal of Drug Targeting·Van Anh Thi NguyenSimon M Cutting
Jun 26, 2014·Critical Reviews in Biotechnology·Sandra R B R SellaCarlos Ricardo Soccol
Jun 10, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Heleen KraanJean-Pierre Amorij
Aug 13, 2014·Microbial Cell Factories·Ezio RiccaRachele Isticato
Sep 23, 2011·Veterinary Ophthalmology·Elizabeth A Giuliano, Kevin Finn
Apr 5, 2015·Molecular Biotechnology·Samira GhaedmohammadiGholamreza Ahmadian
Jun 16, 2012·Human Vaccines & Immunotherapeutics·Hellen Amuguni, Saul Tzipori
Oct 23, 2012·Trends in Biotechnology·Jae-Gu PanChul-Ho Yun
Mar 31, 2015·Vaccine·Luana R M M ApsLuís C S Ferreira
Mar 4, 2014·Colloids and Surfaces. B, Biointerfaces·Giuseppe PesceEzio Ricca
Apr 10, 2015·Nature Communications·I-Lin WuKumaran S Ramamurthi
Aug 30, 2014·FEMS Microbiology Letters·Jae-Gu PanEui-Joong Kim
Jul 23, 2014·FEMS Microbiology Letters·Teja SirecRachele Isticato
May 1, 2016·Journal of Biotechnology·Luana R M M ApsMariana O Diniz
Jan 30, 2014·PloS One·Renata Damásio de SouzaLuís Carlos de Souza Ferreira
Sep 27, 2014·PloS One·Alberta VandiniSante Mazzacane
Sep 10, 2016·Microbial Cell Factories·Giuliana DonadioRachele Isticato
Jan 8, 2017·Applied Microbiology and Biotechnology·He WangRuijin Yang
Aug 21, 2013·Infection and Immunity·Rajko ReljicSimon M Cutting
Sep 23, 2014·Applied and Environmental Microbiology·Giuseppina CangianoEzio Ricca
Mar 15, 2019·Biotechnology and Applied Biochemistry·Garshasb RigiGholamreza Ahmadian
Feb 23, 2020·International Journal of Molecular Sciences·Ana Raquel MaiaLoredana Baccigalupi
Oct 3, 2020·Microbial Cell Factories·Claudia PetrilloRachele Isticato
Nov 22, 2016·Frontiers in Microbiology·Mariamichela LanzilliRachele Isticato
Jul 8, 2020·Applied and Environmental Microbiology·Xiaopei ZhangJiahe Li
Feb 23, 2020·Microbial Cell Factories·Francisco Denis S SantosLoredana Baccigalupi
Jan 3, 2021·Biotechnology Advances·Ezio RiccaRachele Isticato
Oct 30, 2020·International Journal of Biological Macromolecules·Chika Jude Ugwuodo, Tochukwu Nwamaka Nwagu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.